Paracentesis is the standard treatment for refractory ascites in patients with cirrhosis, but it cannot prevent the recurrence of ascites. The placement of a transjugular intrahepatic portosystemic ...
J Gastroenterol Hepatol. 2009;24(9):1494-1503. Transjugular Intrahepatic Portosystemic Shunting. Transjugular intrahepatic portosystemic shunting (TIPS) creates an iatrogenic intrahepatic shunt a ...
WASHINGTON, DC — For patients with acute-on-chronic liver failure (ACLF) undergoing modest-volume paracentesis for ascites, oral midodrine may be an alternative to intravenous albumin for preventing ...
The FDA has granted premarket approval to Sequana Medical’s alfapump implantable device for the treatment of recurrent or refractory ascites due to cirrhosis, according to a company press release.
SANTA MONICA, CA / ACCESSWIRE / October 22, 2019 / BioVie Inc. (OTCQB:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for liver disease, announced ...
Association between a validated symptom assessment tool and nurse clinical impression in patients with cancer admitted to a palliative care unit. This is an ASCO Meeting Abstract from the 2011 ASCO ...
Malignant ascites can develop with late stage pancreatic cancer. Ascites involves the buildup of fluid in the abdomen. Doctors can drain the fluid to relieve symptoms, but fluid may return. Ascites ...
Development of malignant ascites is common in patients with ovarian cancer, and few therapeutic options exist for women with ascites whose tumors become resistant to chemotherapy. Furthermore, in such ...
Arun B. Jesudian, MD: We’ve mentioned GI [gastrointestinal] bleeding, we’ve mentioned hypovolemia, dehydration. Elliot, before you alluded to infections [as] a problem in this population. How do those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback